Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone

J Pediatr Endocrinol Metab. 2008 Nov;21(11):1057-63. doi: 10.1515/jpem.2008.21.11.1057.

Abstract

Background: X-linked severe combined immunodeficiency (XSCID) results from defects in the common cytokine receptor gamma chain (gamma c) required for signaling by receptors for interleukin (IL)-2, -4, -7, -9, -15, and -21. Following haploidentical bone marrow transplant without myelo-conditioning for XSCID, most patients achieve partial reconstitution often limited to T lymphocytes. Many partially corrected patients manifest extreme short stature (<5th percentile). Previous reports have implicated gamma c in growth hormone (GH) receptor signaling, thus severe growth failure in XSCID may be related to the underlying gamma c defect.

Aim: To evaluate the GH/insulin-like growth factor-I (IGF-I) axis in three children with XSCID and partial immune reconstitution with profound growth failure.

Methods: The IGF-I generation test was performed by administering recombinant GH subcutaneously for 5 days, and measuring serum levels for IGF-I before GH injection, and on days 5 and 8.

Results: Study of the somatotropic axis revealed profoundly diminished IGF-I production following rGH challenge in all three patients.

Conclusion: The data indicate that the GH/IGF-I axis in these partially corrected XSCID patients with severe short stature is profoundly impaired, and supports previous studies suggesting that the underlying gamma c defect may contribute to the severe growth failure in XSCID. This supports a role for defective gamma c in the extreme short stature of XSCID, and raises the possibility of recombinant IGF-I treatment to bypass this defect.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adolescent
  • Body Height
  • Body Weight
  • Bone Marrow Transplantation
  • Child
  • Chromosomes, Human, X*
  • Growth Disorders / drug therapy
  • Growth Disorders / genetics*
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Interleukin Receptor Common gamma Subunit / genetics
  • Interleukin Receptor Common gamma Subunit / metabolism
  • Male
  • Recombinant Proteins
  • Reference Values
  • Severe Combined Immunodeficiency / genetics*
  • Severe Combined Immunodeficiency / therapy
  • Treatment Outcome

Substances

  • IL2RG protein, human
  • Interleukin Receptor Common gamma Subunit
  • Recombinant Proteins
  • Human Growth Hormone
  • Insulin-Like Growth Factor I